Recently, following a comprehensive review and multi‑dimensional verification of its documentation by the Jiangsu Provincial Administration for Market Regulation, Taizhou Bolaideli Biotechnology Co., Ltd. was officially recognized as a “2026 Jiangsu Province Quality‑Credit Grade A Enterprise.” This designation represents an authoritative, official assessment by the province’s market regulatory authorities of the company’s quality management, compliant operations, and credit‑building efforts, and stands as a significant honor attesting to the company’s longstanding commitment to pet‑related biopharmaceuticals and its unwavering dedication to quality and integrity.

The entire A‑level application process was conducted in strict compliance with established standards. The company submitted, as required, its business license, a quality‑and‑credit commitment letter, and a nearly one‑year‑long specialized credit report covering 44 administrative sectors across the province. Following official verification, the enterprise reported no administrative penalties, violations of laws or regulations, or records of untrustworthiness over the past year, with a flawless credit profile. It successfully completed the preliminary review procedures at both the district and municipal levels within 30 working days and passed all evaluation criteria on the first attempt.

Deeply rooted in the pet‑care R&D sector, an overview of Bolaideli’s core strengths.

Taizhou Bolaideli established itself in Taizhou China Pharmaceutical City in 2018. It is a national-level high-tech enterprise, a Jiangsu Province “Specialized, Refined, Distinctive, and Innovative” Little Giant, and a provincial Gazelle Enterprise, integrating pet‑new‑drug R&D, GMP‑compliant manufacturing, nationwide distribution, and third-party pet health testing. The company also serves as the co‑vice president of both the Pet Industry Branch of the Chinese Veterinary Association and the Pet Industry Branch of the China Animal Husbandry Association, and stands as a benchmark for domestically produced pet health products.

I. High-Standard Production and Quality Control: Laying a Solid Foundation for Quality and Trust

The company has invested RMB 280 million to build a 24,000-square-meter, EU‑standard, fully functional production base, with dedicated zones for biologics, chemical drugs, testing, and laboratory research. Its entire production line is GMP‑compliant across all veterinary drug categories, its laboratories are accredited by CNAS, and it holds dual GCP clinical trial qualifications for both biologics and chemical drugs, ensuring comprehensive industry compliance.

The enterprise rigorously implements the Chief Quality Officer system, establishes a comprehensive quality‑credit management organizational framework, conducts regular company‑wide training on quality and integrity, and has put in place a digital traceability system covering raw materials, production, warehousing, and after-sales service, along with an end-to‑end quality risk‑management mechanism. In addition, it has refined its metrology and standardization management systems, fully aligning with all assessment criteria for provincial‑level quality‑credit certification.

II. Upholding independent original research and development, multiple products have broken the import monopoly.

The company is dedicated to the research and development of innovative veterinary medicines, having established four specialized R&D platforms. It has secured a total of nine national new‑veterinary‑drug registration certificates and holds more than ten domestic and international invention patents. Its core proprietary products include the world’s first Class I novel veterinary drug—canine serum albumin—China’s first large‑scale, commercially available feline trivalent inactivated vaccine, and a globally unique dual‑purpose recombinant feline interferon. Moreover, numerous original technologies have filled critical gaps in the domestic industry, significantly accelerating the localization and substitution of pet pharmaceuticals.

III. Upholding Compliance and Integrity, and Continuously Fulfilling Industry Social Responsibility

Over the years, the company has maintained an outstanding credit record—zero penalties and zero instances of untrustworthiness across all business areas—while simultaneously obtaining numerous national and provincial-level certifications. Committed to long-term industry development, the company has established a veterinary talent award fund and university‑level scholarships, actively participated in the formulation of industry standards, and regularly organized public‑education initiatives on pet health. It has also put in place a closed-loop customer satisfaction feedback system, proactively welcomes oversight from the market and society, and fulfills its corporate social responsibility in a tangible manner.

Bolaideli will steadfastly uphold its core values of “building a brand through quality and creating the extraordinary from the ordinary,” taking its designation as a provincial-level Grade A enterprise in quality and credit as a new starting point. The company will continue to set a benchmark for quality and integrity in China’s pet biopharmaceutical sector, thereby contributing to the high‑quality, standardized, and trustworthy development of China’s pet industry.